BMS Receives Priority Review for Breyanzi in 2L LBCL; Breyanzi’s PDUFA Date Set for June 24, 2022

On Thursday, February 17, BMS announced (press release) that the FDA has granted a Priority Review for Breyanzi (CD19 CAR-T) in 2L LBCL, with a PDUFA date of June 24, 2022. Below, Celltelligence provides additional thoughts on how Breyanzi’s anticipated US approval in the 2L setting compares with Yescarta (Gilead / Kite; CD19 CAR-T).

About The Author

The Celltelligence Team

Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.


You’ll be able to access the full article from your Celltelligence Library after signing up.